KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib

Fearon, 1990, A genetic model for colorectal tumorigenesis, Cell, 61, 759, 10.1016/0092-8674(90)90186-I Jones, 2008, Comparative lesion sequencing provides insights into tumor evolution, Proc Natl Acad Sci USA, 105, 4283, 10.1073/pnas.0712345105 Andreyev, 2001, Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study, Br J Cancer, 85, 692, 10.1054/bjoc.2001.1964 Bazan, 2002, Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype, Ann Oncol, 13, 1438, 10.1093/annonc/mdf226 Locker, 2006, ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer, J Clin Oncol, 24, 5313, 10.1200/JCO.2006.08.2644 Bokemeyer, 2009, Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer, J Clin Oncol, 27, 663, 10.1200/JCO.2008.20.8397 Van Cutsem, 2008, KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience, J Clin Oncol, 26 Amado, 2008, Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer, J Clin Oncol, 26, 1626, 10.1200/JCO.2007.14.7116 Adelstein, 2011, A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer, Eur J Cancer, 47, 1343, 10.1016/j.ejca.2011.03.031 Jimeno, 2009, KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection, J Clin Oncol, 27, 1130, 10.1200/JCO.2008.19.8168 Allegra, 2009, American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy, J Clin Oncol, 27, 2091, 10.1200/JCO.2009.21.9170 Maughan, 2011, Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial, Lancet, 377, 2103, 10.1016/S0140-6736(11)60613-2 Douillard, 2010, Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study, J Clin Oncol, 28, 4697, 10.1200/JCO.2009.27.4860 Suenaga, 2010, Potential markers predicting bevacizumab efficacy for metastatic colorectal cancer patients, J Clin Oncol, 28 Price, 2011, Impact of KRAS and BRAF gene mutation status on outcomes from the Phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer, J Clin Oncol, 29, 2675, 10.1200/JCO.2010.34.5520 Ince, 2005, Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab, J Natl Cancer Inst, 97, 981, 10.1093/jnci/dji174 Hurwitz, 2009, The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer, Oncologist, 14, 22, 10.1634/theoncologist.2008-0213 Wedge, 2005, AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer, Cancer Res, 65, 4389, 10.1158/0008-5472.CAN-04-4409 Chen, 2009, Phase I study of cediranib in combination with oxaliplatin and infusional 5-fluorouracil in patients with advanced colorectal cancer, Clin Cancer Res, 15, 1481, 10.1158/1078-0432.CCR-08-0761 Hoff, 2012, Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, Phase III study (HORIZON II), J Clin Oncol, 30, 3596, 10.1200/JCO.2012.42.6031 Cunningham, 2008, A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): final PFS results, J Clin Oncol, 26 Kato, 2012, Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised Phase II part of a Phase I/II study, Ann Oncol, 23, 933, 10.1093/annonc/mdr359 Newton, 1989, Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS), Nucleic Acids Res, 17, 2503, 10.1093/nar/17.7.2503 Whitcombe, 1999, Detection of PCR products using self-probing amplicons and fluorescence, Nat Biotechnol, 17, 804, 10.1038/11751 Forbes, 2010, COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer, Nucleic Acids Res, 38, D652, 10.1093/nar/gkp995 Wellcome Trust Sanger Institute. The Catalogue Of Somatic Mutations In Cancer (COSMIC) database. 22 July 2011. Available from http://www.sanger.ac.uk/genetics/CGP/cosmic/. Vaughn, 2011, Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer, Genes Chromosomes Cancer, 50, 307, 10.1002/gcc.20854 Roth, 2010, Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial, J Clin Oncol, 28, 466, 10.1200/JCO.2009.23.3452 Janakiraman, 2010, Genomic and biological characterization of exon 4 KRAS mutations in human cancer, Cancer Res, 70, 5901, 10.1158/0008-5472.CAN-10-0192 De Roock, 2010, Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab, JAMA, 304, 1812, 10.1001/jama.2010.1535 De Roock, 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, Lancet Oncol, 11, 753, 10.1016/S1470-2045(10)70130-3 Hawkes, 2010, Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?, Lancet Oncol, 11, 1020, 10.1016/S1470-2045(10)70211-4 Richman, 2009, KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial, J Clin Oncol, 27, 5931, 10.1200/JCO.2009.22.4295 Ogino, 2009, KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803, Clin Cancer Res, 15, 7322, 10.1158/1078-0432.CCR-09-1570